Motivated by a strong will to offer Institut Pasteur (IP) Paris’ campus a robust, rich and auspicious technological environment, the Executive Scientific Division identified 4 Technology-Targeted Actions (ATC), launched in 2021.
Among them, the Drug Discovery & Screening ATC (ATC–DDS) aims to foster multidisciplinary and translational collaborative projects between IP Paris research laboratories and the PF-CCB Core Facility of the ATC to federate all IP Paris’ workforces (biologists and chemists) around Drug Discovery & Screening to tackle a large variety of diseases covered by the Institut Pasteur 2019-2023 Strategic Plan: emerging infectious diseases such as Covid-19, antimicrobial resistance (bacteria, fungi, viruses, parasites..), neurological disorders, cancers etc.
The ATC-DDS has the pleasure to invite you all to its first Drug Discovery & Screening Symposium which will be held on November 21st, 2022 at the Institut Pasteur campus (Amphitheater Agnes Ullmann).
The symposium will include internal and external keynote speakers, presentations around Drug Discovery & Screening activities at IP, its processes, and exemplified with numerous IP success stories of these fruitful biology-chemistry collaborations from various laboratories of the Institut Pasteur. It will also be a time for discussions around the future of DDS and how to prepare to it.
SCIENTIFIC ORGANIZATION COMMITTEE
- Fabrice Agou
- Nienke Buddelmeijer
- Iuliana Ene
- Ludovic Sauguet
- Olivier Sperandio
The meeting is open to all the members of the Institut Pasteur Paris campus and Pasteur Network : students, researchers and support staff welcome !
The event is free but prior registration is required: Sign up